小方制药 (603207)
Shanghai Xiao Fang Pharmaceutical Co., Ltd.
K-Line Chart
No K-line data available
Company NameShanghai Xiaofang Pharmaceutical Co., Ltd.
Listing Date2024-08-26
Issue Price12.47RMB
Registered Capital16055.996710k RMB
Legal RepresentativeFang Zhiguang
Registered AddressNo. 777 Hongzhu Road, Fengxian District, Shanghai
IndustryChemical Pharmaceuticals
Main BusinessResearch, development, production, and sales of external-use drugs.
Company ProfileShanghai Xiaofang Pharmaceutical Co., Ltd. is primarily engaged in the research, development, production, and sales of external-use drugs. Its products possess strong competitiveness and high market recognition. The company adheres to the corporate mission of 'Providing reliable household medicines, bringing Xiaofang Pharmaceutical into every home,' offering patients a comprehensive range of external-use drugs with stable efficacy and excellent quality. The 'Xinlong' trademark, created in 2002 and continuously used since, enjoys high market recognition. Various external-use drug products under the brand, such as Glycerol Enema, Glycerin Suppository, Calamine Lotion, Zinc Oxide Ointment, Salicylic Acid Ointment, Iodine Glycerin, and Furacilin and Ephedrine Nasal Drops, consistently maintain leading market shares.
Currently, the company holds 63 drug approvals, including 12 national essential drug specifications and 28 national medical insurance varieties. Its main product, Glycerol Enema, is listed in the National Development and Reform Commission's catalog of low-priced drugs.
In the future, the company will further strengthen R&D innovation, expand product categories and dosage forms, and continuously meet the disease treatment and daily care needs of ordinary households.
Stock Details
1. Key Indicators
- Total Shares(W): 16056.00
- Circulating A-Shares(W): 5440.00
- Earnings Per Share(RMB): 1.0600
- Net Assets Per Share(RMB): 6.5651
- Operating Revenue(W RMB): 39721.86
- Total Profit(W RMB): 19831.73
- **Net Profit Attributable to Parent(W RMB) **: 16989.40
- Net Profit Growth Rate(%): 5.09
- Weighted Return on Equity(%): 14.1500
- Operating Cash Flow Per Share(RMB): 0.8340
- Undistributed Profit Per Share(RMB): 2.1769
- Capital Reserve Per Share(RMB): 3.0395
2. Main Business
The main business covers:
- Research, development, production, and sales of external medicines
3. Company Basic Information
- Company Name: Shanghai Xiaofang Pharmaceutical Co., Ltd.
- Listing Date: 2024-08-26
- Industry: Pharmaceutical Manufacturing
- Address: No. 777 Hongzhu Road, Fengxian District, Shanghai
- Website: https://www.xf-pharma.com
- Company Profile: The company was established through the overall change of Yunjia Co., Ltd. into a joint stock company, with the audited net assets as of August 31, 2021, converted into shares. The industrial and commercial change registration was completed on December 24, 2021. It is mainly engaged in the research, development, production, and sales of external medicines.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Shandong New Era Private Fund Management Co., Ltd. - Shandong Province New Kinetic Energy Linghang Medical Care Equity Investment Fund Partnership (Limited Partnership) | General Legal Person | 240.00 | 4.41 |
| 2 | Laobaixing Pharmaceutical Group Co., Ltd. | General Legal Person | 156.39 | 2.87 |
| 3 | Guoxin Capital Co., Ltd. | General Legal Person | 97.00 | 1.78 |
| 4 | China Foreign Economic and Trade Trust Co., Ltd. - Foreign Trade Trust - Renqiao Zeyuan Stock Private Securities Investment Fund | Private Securities Investment Fund | 80.84 | 1.49 |
| 5 | GF Duoyuan Emerging Stock Securities Investment Fund | Fund | 75.31 | 1.38 |
| 6 | China National Petroleum Corporation Enterprise Annuity Plan - Industrial and Commercial Bank of China Co., Ltd. | Annuity | 67.94 | 1.25 |
5. Concept Sectors
- Medical Aesthetics Concept
- Innovative Drugs
- Margin Trading & Securities Lending
- High-Performance Stocks
- High Dividend Stocks
- Stocks Listed Within Two Years
Remarks
- Data update date: 2025-09-30
- Data source: Public Market Information